Recent News
Revive Therapeutics Ltd. Announces Offering of Up to $5 Million
...
Revive Therapeutics Announces Update for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
...
Revive Therapeutics Announces FDA Recommendation for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
...
Revive Therapeutics Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA
...